HSBC Issues Rare Sell Rating on High-Flying Pharma Giant Eli Lilly

In a move that sent shockwaves through the market, global banking giant HSBC has downgraded its stance on Eli Lilly & Co. to “Reduce,” a rare sell recommendation for one of Wall Street’s most favored pharmaceutical stocks. The bank simultaneously slashed its price target from $1,070 to $850. The reaction was swift and severe: on Tuesday, Eli Lilly shares tumbled nearly 6%, ranking among the session’s worst performers.

Valuation Concerns Clash with Operational Strength

The downgrade centers on a fundamental disagreement about the future of the obesity drug market, a key driver behind Lilly’s soaring valuation. While the prevailing analyst consensus projects an addressable market exceeding $150 billion, HSBC’s analysis presents a far more conservative outlook. The bank forecasts a market size of only $80 to $120 billion by 2032 and anticipates significant price pressure within the GLP-1 drug segment.

These concerns are amplified by Lilly’s current valuation metrics. The stock trades at a price-to-earnings ratio of approximately 43, a substantial premium to the industry average of 17.4. This lofty multiple leaves little room for any operational missteps or market disappointments.

Scrutiny Falls on Oral Obesity Drug and Business Model

HSBC’s skepticism extends specifically to orforglipron, Lilly’s oral obesity pill slated for a potential FDA approval decision in April. The bank contends that market expectations for the drug are overly optimistic. It points to high discontinuation rates in clinical trials, which it argues are incompatible with assumed patient compliance levels.

Furthermore, HSBC highlights a potential structural vulnerability in the direct-to-consumer payment model for these treatments. Citing IQVIA data, it notes that nearly 80% of prescriptions for Novo Nordisk’s oral Wegovy are paid for out-of-pocket, without insurance coverage. This exposes the segment to risk, as consumers might quickly cut back on such discretionary health spending during an economic downturn.

Should investors sell immediately? Or is it worth buying Eli Lilly?

Strong Financial Performance Continues Unabated

This cautious outlook stands in stark contrast to Eli Lilly’s formidable operational and financial results. The company reported fourth-quarter 2025 revenue of $19.29 billion, a surge of 42.6% year-over-year that comfortably beat consensus estimates. Sales of its drugs Mounjaro and Zepbound more than doubled. Looking ahead, management has provided full-year 2026 revenue guidance of $80 to $83 billion.

The bullish case for the stock remains firmly intact among most Wall Street researchers. Of the 30 analysts covering Eli Lilly, 26 maintain a “Buy” or equivalent rating. Just days before the HSBC report, on March 16, RBC Capital Markets reaffirmed its “Outperform” rating, citing the upcoming launch of orforglipron as a key catalyst.

Pivotal Catalyst on the Horizon

All eyes are now on the FDA’s April decision regarding orforglipron, which will serve as an immediate test for market sentiment. Phase 3 trial data indicated that patients switching from injectable therapies to the oral pill were able to maintain their weight loss. This finding suggests the treatment could significantly expand the market by appealing to patients averse to injections.

In a show of confidence, Eli Lilly announced in early March a planned $3 billion investment over the next decade to build production capacity for orforglipron in China.

Over the past twelve months, Eli Lilly has dramatically outperformed its chief rival, Novo Nordisk, whose shares declined roughly 55% over the same period. Whether this outperformance continues will hinge largely on which market forecast proves more accurate: the bullish consensus or HSBC’s decidedly more sober estimates.